TriveniBio
PrivateLast Round
Series C
Jun 17, 2026
Est. Valuation
$390.53M
Total Funding Raised
$272M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
TriveniBio is a clinical-stage biotechnology company developing novel antibody-based therapies for immunological and inflammatory disorders using a genetics-informed approach.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TriveniBio Comparables
Compare TriveniBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Roche Holding | 75% | |
| Bionyra Pharma | 74% | |
| AbbVie | 74% |
TriveniBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 17, 2026 | ||||
| Series B | Oct 2, 2024 | ||||
| Series A | Oct 26, 2023 |
Key People
Founding team and executive leadership
TriveniBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Fidelity Management & Research Company | Series B |
| Deep Track Capital | Series C, Series B |
| OrbiMed | Series B, Series A |
| Cormorant Capital | Series A |
| Invus Opportunities | Series B, Series A |
| Viking Global Investors | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
$65M round led by Janus Henderson Group and Ascenta Capital
- Nov 1, 2025
Developing an IL-13 targeting asset for atopic dermatitis.
Recent news
Latest coverage and updates
- is_developingJun 29, 2026
Triveni Bio Inc. is developing BYN-003 on Jun 1st '26.
- identified_as_competitor_ofJun 17, 2026
Triveni Bio Inc. identified as competitor of Centrosepharma on Jun 17th '26.
- hiresJun 17, 2026
Triveni Bio Inc. hired Evan Rachlin as Board of Directors on Jun 17th '26.
- receives_financingJun 17, 2026
Triveni Bio, Inc. received financing of $65M in Series C on Jun 17th '26.
TriveniBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TriveniBio's valuation, stock price, and market status.
Is TriveniBio a public or private company?
TriveniBio is a private company.
What is the current stock price of TriveniBio?
TriveniBio is a private company with no public stock price. No recent secondary market data is available.
How much is TriveniBio worth (valuation)?
TriveniBio's valuation is estimated at $390.5M based on funding round data.
Can I buy TriveniBio stock?
TriveniBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was TriveniBio's last funding round?
TriveniBio's most recent funding round was Series C on June 17, 2026.
Who are the main investors in TriveniBio?
Key investors in TriveniBio include Janus Henderson Group, Cormorant Capital, Goldman Sachs Group, Inc., Atlas Venture, Cormorant Asset Management.
Will TriveniBio IPO soon?
No public IPO plans have been announced for TriveniBio.
How can I track TriveniBio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TriveniBio's secondary market activity and sign up for updates.